Details of the Drug

General Information of Drug (ID: DM91KZL)

Drug Name

SAR445877

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Fusion protein

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-15 (IL15)	TTJFA35	IL15_HUMAN	Not Available	[2]
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Aggressive cancer

ICD Disease Classification

2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Programmed cell death protein 1 (PD-1)	DTT	PDCD1	7.26E-01	-0.01	-0.03

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05584670) A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Sanofi